

AWARD NUMBER: W81XWH-13-1-0403

TITLE: Study of Rpl22 in MDS and AML

PRINCIPAL INVESTIGATOR: Shuyun Rao, Ph.D.

RECIPIENT: The Institute for Cancer Research
Philadelphia, PA 19111 December 2016

REPORT DATE: December 2016

TYPE OF REPORT: Final

PREPARED FOR: U.S. Army Medical Research and Materiel Command
Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT:
Approved for public release; distribution unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

REPORT DOCUMENTATION PAGE				<i>Form Approved</i> OMB No. 0704-0188	
Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Department of Defense, Washington Headquarters Services, Directorate for Information Operations and Reports (0704-0188), 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302. Respondents should be aware that notwithstanding any other provision of law, no person shall be subject to any penalty for failing to					
1. REPORT DATE (DD-MM-YYYY) December 2016		2. REPORT TYPE Final		3. DATES COVERED (From - To) 30 Sep 2013 - 29 Sep 2016	
4. TITLE AND SUBTITLE Study of Rpl22 in MDS and AML				5a. CONTRACT NUMBER	
				5b. GRANT NUMBER W81XWH-13-1-0403	
				5c. PROGRAM ELEMENT NUMBER	
6. AUTHOR(S) Shuyun Rao, Ph.D. raoshuyun@gmail.com				5d. PROJECT NUMBER	
				5e. TASK NUMBER	
				5f. WORK UNIT NUMBER	
7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) The Institute for Cancer Research 333 Cottman Avenue Philadelphia, Pennsylvania 19111				8. PERFORMING ORGANIZATION REPORT	
9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES) U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012				10. SPONSOR/MONITOR'S ACRONYM(S)	
				11. SPONSOR/MONITOR'S REPORT NUMBER(S)	
12. DISTRIBUTION / AVAILABILITY STATEMENT ✓ Approved for public release; distribution unlimited					
13. SUPPLEMENTARY NOTES					
14. ABSTRACT <p>Increasing evidence from our lab and others suggests that ribosomal proteins play a critical regulatory role in development and disease, including bone marrow disease, that can be mediated independently of their functions in ribosomal biosynthesis. Previously I have determined that ribosomal protein Rpl22 functions as a haploinsufficient tumor suppressor by activating NFκB and its target Lin28B in a mouse T-cell lymphoma model driven by Myr-Akt2. Recently we also found that Rpl22 knockout mice exhibit an MDS-like phenotype associated with anemia and abnormal bone marrow (BM) hematopoiesis. Consistently, our collaborator found that <i>RPL22</i> indeed was mutated or deleted in some MDS and AML patients. Further we found that loss of Rpl22 but not other ribosomal proteins induces Lin28B, and the activation of NFκB and Lin28B mainly depends on ER stress signaling through PERK. Rpl22 has a homolog Rpl22-Like1 (Like1) that is induced upon <i>Rpl22</i> loss. Interestingly, Rpl22 functions through the regulation of Like1. Like1 overexpression is both necessary and sufficient for both transformation and NFκB-mediated Lin28B induction. Mechanistic studies revealed that Rpl22 directly bind to Like1 mRNA and inhibit its translation. Through MLL-AF9 AML BM transplant mouse model, I found that Rpl22 inactivation accelerates AML progression and correlated with poor survival. We are still in the progress of investigate Rpl22 and its paralog Like1 in MDS/AML and hopefully can find out new therapeutic target through these efforts.</p>					
15. SUBJECT TERMS Rpl22, MDS, AML, MLL-AF9, ER stress, Rpl22-Like1					
16. SECURITY CLASSIFICATION OF:			17. LIMITATION OF ABSTRACT Unclassified	18. NUMBER OF PAGES 20	19a. NAME OF RESPONSIBLE PERSON USAMRCA
a. REPORT Unclassified	b. ABSTRACT Unlimited	c. THIS PAGE Unclassified			19b. TELEPHONE NUMBER

TABLE OF CONTENTS

Introduction.....	4
Keywords.....	4
Overall Project Summary.....	4
Key Research Accomplishments.....	8
Conclusion.....	8
Publications, Abstracts, and Presentations.....	9
Inventions, Patents, and Licenses.....	9
Reportable Outcomes.....	9
Other Achievements.....	9
Training and Professional Development Activities.....	9
References.....	10
Appendices.....	10

INTRODUCTION:

Ribosomal proteins (RPs) have been well known to be essential for protein synthesis. Increasing evidence from our lab and others suggests that RP play a critical but poorly understood role in development as well as disease. Mutations in RPs cause a group of diseases collectively termed ribosomopathies, which are mainly bone marrow failure diseases and are often associated with increased risk for development of myeloid neoplasms. We are interested in Rpl22, an RNA-binding component of the 60S ribosomal subunit. Rpl22 is dispensable for protein biosynthesis but plays a role in regulating transformation and hematopoiesis (1, 3). Previously I have determined that Rpl22 functions as a haploinsufficient tumor suppressor, whose mono-allelic inactivation can accelerate the development of T-cell lymphoma in a mouse model where disease is driven by an MyrAkt2-transgene. Rpl22 inactivation predisposes to transformation by activating the NF κ B and its direct target, the stem cell factor Lin28B (3). In addition, we also found that Rpl22 knockout mice exhibit an MDS-like phenotype associated with anemia and abnormal bone marrow (BM) hematopoiesis. Consistent with what we observed in our mouse model, our collaborator found that Rpl22 was mutated or deleted in some MDS and AML patients. Based on these data, I intend to investigate the role of Rpl22 in MDS and its predisposition of AML and hopefully can find out new therapeutic target through these efforts. Rpl22 has a paralog Rpl22-like1 (Like1) that shares 70% sequence identity with Rpl22 (1, 4), and I found that Like1 is induced by Rpl22 inactivation both in vivo and in vitro. These results led me to further explore the role of Rpl22 and its paralog Like1 in the predisposition of blood malignancies as well.

KEYWORDS: Rpl22, MDS, AML, MLL-AF9, ER stress, Rpl22-Like1

OVERALL PROJECT SUMMARY:

1. To explore the molecular basis for Lin28B induction by inactivation of Rpl22




Figure 1. NF κ B/Lin28B induction depends on ER stress PERK/eIF2 α pathway. **A**, Schematic to show the activation of NF κ B through ER stress PERK signaling. **B**, western blot to show that Rpl22 loss increases PERK-eIF2 α activation as displayed by phospho-PERK and phospho-eIF2 α . **C**, western blot to show that Lin28B induction is dependent on PERK.

1A: Test whether Rpl22 loss activates NFκB through endoplasmic reticulum stress pathway PERK-phospho-eIF2α-IκBα or IRE1α-TRAF-IKKβ

Recent publications have showed ER stress activation of NFκB signaling (5) and we observed increased ER stress response in Rpl22-deficient cells as demonstrated here (**Fig.1A,B**) by increased phospho-PERK and its target phospho-EIF2α. Therefore, we utilized retroviral-mediated shRNA targeting different ER stress components including PERK, IRE1α, and ATF6 to determine which signaling pathway is required for Lin28B induction. As shown in **Fig.1C**, knockdown of PERK significantly reduced NFκB activation as displayed by phospho-NFκB and Lin28B induction. We did not see significant differences upon ATF6 knockdown. These data support that PERK signaling is responsible the activation NFκB activation and Lin28B induction.

1B. NFκB/Lin28B induction caused by Rpl22 inactivation also relies on Rpl22 paralog Rpl22-Like1




Figure 2. Lin28B induction and transformation induced by Rpl22 inactivation depends on Rpl22 paralog Like1. **A**, western blot to show Like1 induction upon Rpl22 knockdown by shRNA. **B**, western blot to show that Rpl22 loss leads to Lin28B induction and knockdown of Like1 abrogates Lin28B induction. **C**, western blot to show knockdown of Like1 by two different shRNAs. **D**, western blot to show that Like1 overexpression (L1-HA) increases NFκB signaling and Lin28B induction. GAPDH is used as loading control for all western. **E-F**, colony formation assay to show that knockdown of Like1 (**E**) abrogates or overexpression of Like1-HA promotes (**F**) transformation caused by Rpl22 loss. **G**, Survival curve of Like1 knockout mice in T-cell lymphoma model driven by MyrAkt2.

I also made an interesting finding that links NFκB/Lin28B induction upon Rpl22 loss with Rpl22 paralog, Rpl22-Like1, (Like1) expression. I have found that Like1 is induced upon Rpl22 inactivation (**Fig.2A**). Knockdown of Like1 inhibits Lin28B induction (**Fig.2B,C**) whereas

overexpression of Like1 increases Lin28B levels as well as NF κ B signaling as demonstrated by phosphorylation of p65 (**Fig.2D**). We don't know whether PERK activation depends on Like1 induction yet. We are now investigating whether Like1 is required for ER stress to activate NF κ B signaling and Lin28B induction. Furthermore, I also observed Like1 induction is both necessary and sufficient to promote transformation in colony formation assay (**Fig.2D-F**). Like1 is also critical for disease progression in vivo (**Fig.2G**). All these data suggest that Like1 induction occurs before Lin28B induction and plays critical in transformation. We are now focusing on the role of Like1 in the progression of blood malignancies (6, 7) and other solid tumors (8) because Like1 amplification was found in these diseases. I also further explored the molecular mechanism associated with the post-transcriptional regulation of Like1 by Rpl22 and found out that Rpl22 directly binds to Like1 mRNA and inhibits its translation (**Fig.3**) but not protein degradation (data not shown).




Figure 3. Rpl22 binds to Like1 mRNA for its translational inhibition. **A**, RNA-IP to demonstrate that Rpl22 directly binds to Like1 mRNA. **B**, western blot (top) to show that intact Rpl22, but not mutant Rpl22 (m88) that cannot bind RNA, inhibits Like1 protein expression not mRNA levels (bottom). **C**, Polysome profiling to demonstrate that Rpl22 inactivation leads to more Like1 mRNA accumulation in polysome fraction where active translation occurs.

1C. To determine whether inactivation of other ribosomal proteins increases Lin28B

By knockdown other ribosomal proteins with lentiviral mediated shRNA targeting Rps7, Rpl36, Rpl36a, Rps19 and Rpl14, we failed to observe significant induction of Lin28B as determined by realtime PCR (**Fig.4**). These data suggest that regulation of Lin28B is specific with Rpl22.




Figure 4. Lin28B mRNA levels were determined by realtime PCR after 72 hours of shRNA infection targeting ribosomal protein Rps7, Rpl36, Rpl36a, Rps19 and Rpl14.

2. To assess the role of p53 induction in the perturbation of hematopoiesis observed in *Rpl22*^{-/-} mice

Ribosomal protein defects frequently induce p53 (9, 10). To assess the role of p53 in perturbation of hematopoiesis in *Rpl22*^{-/-} mice, p53 null mice were crossed with *Rpl22*^{-/-} mice. We examined p53 levels in the bone marrow from *Rpl22* wild type (WT) and knockout (KO) mice and found out p53 is not dramatically altered in bone marrow cells, particularly upon enriching for stem/progenitor cells by depleting cells expressing lineage markers (**Fig.5**). We also analyzed the phenotype in *Rpl22*^{-/-}p53^{-/-} mice and found that the mice exhibit similar phenotype with *Rpl22*^{-/-}. We also did RNA-seq analysis and real-time PCR in the bone marrow cells from *Rpl22* WT and



Figure 5. Western blot to show p53 expression levels in bone marrow cells (BM) isolated from *Rpl22* wild type (WT) or knockout mice (KO) with or without lineage depletion (Lin Dep.) and 2 days or 5 days 5-Fu treatment. Actin is used as loading control.

Rpl22 KO and found out the p53 targets were not altered significantly except p21. Based on this, we assume that p53 may not significantly influence hematopoiesis in *Rpl22* KO mice.

3. To explore whether *Rpl22* loss accelerates Myelodysplastic Syndrome /Acute Myelogenous Leukemia progression

We used MLL-AF9, a frequent translocation in AML with oncogenic activity in murine models (11, 12). Mice transplanted with MLL-AF9 expressing cells displayed leukemia phenotype as early as 6 weeks (13). So we transduced BM cells from *Rpl22*^{-/-} and *Rpl22*^{+/+} mice with MLL-AF9 and transplanted the cells into the recipient mice. As we expected, mice receiving *Rpl22* KO cells display AML phenotype as shown in **Fig.6**. *Rpl22* loss seems to be predisposed to AML.




Figure 6. **A.** Schematic to show the transplant mouse model. BM cells were harvested, transduced with MLL-AF9 oncogene and then transplanted to irradiate recipient mice. **B.** Spleen weight of the recipient mice receiving transformed BM cells with MLL-AF9. **C.** Hematocrit of recipient mice receiving BM cells transduced with MLL-AF9.




Figure 7. Percent survival of MLL-AF9 transgenic mice and Rpl22 knockout (Rpl22^{-/-}) mice showed poor survival compared with Rpl22 wild type mice (Rpl22^{+/+}).

We also generated MLL-AF9 transgenic mice with Rpl22 KO to study whether Rpl22 deletion will accelerate AML development *in vivo*. We found Rpl22 knockout MLL-AF9 mice displayed poor survival compared with wild type counterpart (Rpl22^{-/-};MLL-AF9 VS Rpl22^{+/+};MLL-AF9, $p < 0.05$) (**Fig.7**).

KEY PROJECT ACCOMPLISHMENTS:

1. Linked Rpl22 defects with ER stress and PERK signaling and induction of oncogenic targets.
2. Revealed that Rpl22 functions through its paralog Like1 in transformation and Lin28B induction.
3. Found Rpl22 paralog Like1 is a proto-oncogene that is sufficient and necessary for transformation mediated by Rpl22 defects.
4. Revealed that Rpl22 directly binds to Like1 mRNA for translational repression.
5. Although p53 induction occurs upon ribosomal defects and is usually linked with bone marrow disease, our data did not support p53 as the key player in MDS/AML caused by Rpl22 defect.
6. Uncovered a pathological role of Rpl22 defect, in promoting AML progression.

CONCLUSION:

Together, my data provide insights into the mechanism underlying the basis by which Rpl22 defects promote MDS/AML and have linked Rpl22 loss to exacerbation of ER stress PERK signaling. Our survival data in MLL-AF9 transgenic mice strongly suggest that Rpl22 inactivation or deletion might be a poor prognostic marker in AML. Interestingly, I also made the novel observation that the tumor suppressor function of Rpl22 is mediated through repression of its paralog Like1. Like1 is induced upon Rpl22 inactivation and its expression is required and sufficient to promote transformation and Lin28B induction, suggesting Like1 might be a proto-oncogene in tumorigenesis. We are investigating the role of Rpl22 inactivation as well as Like1 induction in the development and progression of blood malignancies as well as solid tumors. We

are also exploring prognostic value of Rpl22 inactivation and Like1 overexpression in both blood malignancies and solid tumors.

PUBLICATIONS, ABSTRACTS, AND PRESENTATIONS:

a. Publications:

- **Rao S**, Cai KQ, Stadanlick JE, Greenberg-Kushnir N, Solanki-Patel N, Lee SY, Fahl SP, Testa JR, Wiest DL. Ribosomal Protein Rpl22 Controls the Dissemination of T-cell Lymphoma. *Cancer Res.* 76 (11): 3387-96, 2016. doi: 10.1158/0008-5472.CAN-15-2698

b. Abstract presented in conference

- **Rao S**, Stadanlick JE, Cai KQ, Wiest DL. 2014. Loss of Rpl22 promotes tumor progression through regulation of angiogenesis and dissemination. AACR-Hematologic Malignancies Conference, Philadelphia, USA (Travel Award)
- Greenberg N, Patel NS, Peri S, **Rao S**, Rhodes M, Wiest DL. 2014. Role of Ribosomal Protein Rpl22 in regulating leukemic transformation. AACR-Hematologic Malignancies Conference, Philadelphia, USA

INVENTIONS, PATENTS AND LICENSES: Nothing to report.

REPORTABLE OUTCOMES:

Developed Like1 antibody and tested for the application of western blot, immunoprecipitation, immunofluorescence and immunohistochemistry (IHC) in tissue microarray.

OTHER ACHIEVEMENTS: Nothing to report.

TRAINING AND PROFESSIONAL DEVELOPMENT ACTIVITIES:

I joined Dr. David Wiest's lab for postdoctoral training in 2010 to study the mechanism by which inactivation of the ribosomal protein Rpl22 predisposes blood malignancies. Dr. Wiest's expertise in preclinical animal models of T cell malignancy as well as in the manipulation of development of primary hematopoietic stem cells in vitro and in vivo, has enabled me to significantly expand my technical repertoire. In my pursuit of these studies, I have developed a strong interest in hematologic malignancies. Under Dr. Wiest's sponsorship I have gone through the following trainings, which is necessary for an independent position in academia: 1) Writing Skills – I have enrolled in the interactive 6wk grant writing course at Fox Chase and improved my writing skills. Additionally, I am preparing two manuscripts (one submitted to *Cancer Research*). This entails several rounds of review and revision with Dr. Wiest, which also helps to improve my writing ability. 2) Oral Presentations – I have won awards for my oral presentations; I also attended weekly Wiest lab meetings, the postdoctoral seminar series, weekly departmental journal club and Fox Chase Research Festival to further improve my speaking ability 3) Research Networking – our weekly departmental seminar series where I am able to meet with the outstanding speakers that visit Fox Chase Cancer Center and scientific meetings. I attended the 2014 AACR-Hematologic Malignancies Conference and 2015 AACR Annual Conference in

Philadelphia. All these experiences ensure that I received a well-rounded training experience and will be fully prepared me for independence as a researcher in blood malignancies. I will also re-submit a K22 grant application this coming year from George Washington, with strong support from Dr. Wiest and the two more manuscripts in progress, I am on my way towards research independence.

REFERENCES:

1. Zhang Y, *et al.* (2013) Control of hematopoietic stem cell emergence by antagonistic functions of ribosomal protein paralogs. *Dev Cell* 24(4):411-425.
2. Narla A & Ebert BL (2010) Ribosomopathies: human disorders of ribosome dysfunction. *Blood* 115(16):3196-3205.
3. Rao S, *et al.* (2012) Inactivation of ribosomal protein L22 promotes transformation by induction of the stemness factor, Lin28B. *Blood* 120(18):3764-3773.
4. O'Leary MN, *et al.* (2013) The ribosomal protein Rpl22 controls ribosome composition by directly repressing expression of its own paralog, Rpl22l1. *PLoS Genet* 9(8):e1003708.
5. Hotamisligil GS (2010) Endoplasmic reticulum stress and the inflammatory basis of metabolic disease. *Cell* 140(6):900-917.
6. Eckerle S, *et al.* (2009) Gene expression profiling of isolated tumour cells from anaplastic large cell lymphomas: insights into its cellular origin, pathogenesis and relation to Hodgkin lymphoma. *Leukemia* 23(11):2129-2138.
7. Andersson A, *et al.* (2007) Microarray-based classification of a consecutive series of 121 childhood acute leukemias: prediction of leukemic and genetic subtype as well as of minimal residual disease status. *Leukemia* 21(6):1198-1203.
8. Ferreira AM, *et al.* (2014) High frequency of RPL22 mutations in microsatellite-unstable colorectal and endometrial tumors. *Hum Mutat* 35(12):1442-1445.
9. Bai D, Zhang J, Xiao W, & Zheng X (2014) Regulation of the HDM2-p53 pathway by ribosomal protein L6 in response to ribosomal stress. *Nucleic Acids Res* 42(3):1799-1811.
10. Liu Y, *et al.* (2014) Ribosomal protein-Mdm2-p53 pathway coordinates nutrient stress with lipid metabolism by regulating MCD and promoting fatty acid oxidation. *Proc Natl Acad Sci U S A* 111(23):E2414-2422.
11. Chen W, *et al.* (2008) Malignant transformation initiated by Mll-AF9: gene dosage and critical target cells. *Cancer cell* 13(5):432-440.
12. Chen W, *et al.* (2006) A murine Mll-AF4 knock-in model results in lymphoid and myeloid deregulation and hematologic malignancy. *Blood* 108(2):669-677.
13. Xu SM, *et al.* (2013) [Establishment of the retrovirus-mediated murine model with MLL-AF9 leukemia]. *Zhongguo Shi Yan Xue Ye Xue Za Zhi* 21(5):1126-1132.

APPENDICES:

- Rao S, Cai KQ, Stadanlick JE, Greenberg-Kushnir N, Solanki-Patel N, Lee SY, Fahl SP, Testa JR, Wiest DL. 2016. Ribosomal Protein Rpl22 Controls the Dissemination of T-cell Lymphoma. *Cancer Res*. 76 (11): 3387-96. doi: 10.1158/0008-5472.CAN-15-2698

Ribosomal Protein Rpl22 Controls the Dissemination of T-cell Lymphoma

Shuyun Rao¹, Kathy Q. Cai², Jason E. Stadanlick¹, Noa Greenberg-Kushnir¹, Nehal Solanki-Patel¹, Sang-Yun Lee¹, Shawn P. Fahl¹, Joseph R. Testa², and David L. Wiest¹

Abstract

Mutations in ribosomal proteins cause bone marrow failure syndromes associated with increased cancer risk, but the basis by which they do so remains unclear. We reported previously that the ribosomal protein Rpl22 is a tumor suppressor in T-cell acute lymphoblastic leukemia/lymphoma (T-ALL), and that loss of just one *Rpl22* allele accelerates T-cell lymphomagenesis by activating NF- κ B and inducing the stem cell factor Lin28B. Here, we show that, paradoxically, loss of both alleles of *Rpl22* restricts lymphoma progression through a distinct effect on migration of malignant cells out of the thymus. Lymphoma-prone AKT2-transgenic or PTEN-deficient mice on an *Rpl22*^{-/-} background developed significantly larger and markedly more vascularized thymic tumors than those observed in *Rpl22*^{+/+} control mice. But, unlike *Rpl22*^{+/+} or *Rpl22*^{+/-} tumors, *Rpl22*^{-/-} lymphomas did not

disseminate to the periphery and were retained in the thymus. We traced the defect in the *Rpl22*^{-/-} lymphoma migratory capacity to downregulation of the KLF2 transcription factor and its targets, including the key migratory factor sphingosine 1-phosphate receptor 1 (S1PR1). Indeed, reexpression of S1PR1 in *Rpl22*-deficient tumor cells restores their migratory capacity *in vitro*. The regulation of KLF2 and S1PR1 by *Rpl22* appears to be proximal as *Rpl22* reexpression in *Rpl22*-deficient lymphoma cells restores expression of KLF2 and S1PR1, while *Rpl22* knockdown in *Rpl22*-sufficient lymphomas attenuates their expression. Collectively, these data reveal that, while loss of one copy of *Rpl22* promotes lymphomagenesis and disseminated disease, loss of both copies impairs responsiveness to migratory cues and restricts malignant cells to the thymus. *Cancer Res*; 76(11); 3387–96. ©2016 AACR.

Introduction

Evidence is emerging suggesting that some ribosomal proteins (RP) play critical roles in regulating development and disease (1–3) that are likely to be exerted outside of the ribosome. One such RP, Rpl22, is an RNA-binding component of the 60S ribosomal subunit, whose normal physiologic function remains poorly understood. Rpl22 is dispensable for ribosome biogenesis and global, cap-dependent translation; however, Rpl22 does play a critical, lineage-restricted role in supporting hematopoiesis (4, 5). Indeed, despite the ubiquitous expression of Rpl22, *Rpl22*-null mice are viable and fertile, with the only obvious defect being an exquisitely specific p53-dependent block in certain lymphoid subsets, including $\alpha\beta$ lineage T cells (5, 6). The tissue-restricted nature of the developmental abnormalities caused by *Rpl22* deficiency, clearly distinguish Rpl22 from other RPs, whose loss usually results in early lethality (3, 7). Because of its important role in normal T-cell development, we evaluated whether Rpl22 might regulate the development of T-cell malignancies. We determined that Rpl22 is capable of functioning as a haploinsufficient

tumor suppressor in T-cell acute lymphoblastic leukemia/lymphoma (T-ALL). Indeed, loss of one copy of *Rpl22*, which does not affect normal T-cell development, markedly accelerated the development of thymic lymphoma in a mouse T-ALL model that uses a myristoylated, oncogenic Akt2 (*MyrAkt2*) transgene (Tg). Monoallelic inactivation of *Rpl22* in this *MyrAkt2* Tg background enhances development of thymic lymphoma by activation of NF- κ B and its target, Lin28B (2). Notably, *RPL22* inactivation is observed in ~10% of human T-ALL (2), where its loss correlates with poor survival. Mono-allelic inactivation or deletion of *RPL22* has also been observed in endometrial and colorectal cancer (8, 9).

While monoallelic inactivation of *RPL22* has been reported in human T-ALL and other solid tumors (8, 9), to date biallelic mutations and/or deletions of *RPL22* have only been reported in solid tumors (9). Given that mono- and biallelic inactivation of tumor suppressor genes sometimes results in distinct prognostic and phenotypic characteristics in the resulting cancers (10, 11), we wished to assess the impact of eliminating both *Rpl22* alleles on T-ALL development and progression, as this has not previously been investigated. This was also of particular interest because biallelic inactivation of *Rpl22* in the germline results in the arrest of T-cell development (5), suggesting that complete loss of Rpl22 (*Rpl22*^{-/-}) might actually delay the development of disease relative to the acceleration observed under conditions of haploinsufficiency (*Rpl22*^{+/-}). To test this hypothesis, we used two different T-cell lymphoma models with constitutive activation of the Akt pathway, which is frequently observed in human T-ALL. Indeed, Gutierrez and colleagues reported alterations of the PTEN–PI3K–Akt pathway in nearly 50% of pediatric T-ALL (12). The two models used were a *MyrAkt2* Tg mouse, in which *MyrAkt2* is expressed in T-lineage progenitors under the control of

¹Blood Cell Development and Function Program, Fox Chase Cancer Center, Philadelphia, Pennsylvania. ²Cancer Biology Program, Fox Chase Cancer Center, Philadelphia, Pennsylvania.

Note: Supplementary data for this article are available at Cancer Research Online (<http://cancerres.aacrjournals.org/>).

Corresponding Author: David L. Wiest, Fox Chase Cancer Center, Room 383A, Reimann Building, 333 Cottman Avenue, Philadelphia, PA 19111. Phone: 215-728-2966; Fax: 215-728-2412; E-mail: david.wiest@fccc.edu

doi: 10.1158/0008-5472.CAN-15-2698

©2016 American Association for Cancer Research.

a proximal Lck promoter (13) and a conditional knockout mouse where the *Pten* tumor suppressor gene is ablated in T-cell precursors using pre-T α -Cre (14). Interestingly, both enforced expression of *MyrAkt2* and biallelic loss of *Pten* resulted in a partial rescue of the block in T-cell development caused by *Rpl22* deficiency. Moreover, to our surprise, *Rpl22*-deficiency resulted in a thymic lymphoma phenotype distinct from that observed in *Rpl22* heterozygous (*Rpl22*^{+/-}) or wild-type (*Rpl22*^{+/+}) mice. Indeed, in *Rpl22*^{+/+} and *Rpl22*^{+/-} mice, thymic lymphoma rapidly disseminated from the thymus to peripheral organs, including lymph nodes, spleen, and liver. In contrast, in *Rpl22*^{-/-} mice, the thymic lymphoma did not disseminate or migrate to peripheral organs, was retained mediastinally, and exhibited markedly enhanced angiogenesis. The absence of dissemination was associated with a marked reduction in expression of the KLF2 transcription factor, which controls the expression of some critical regulators of T-cell migration, including S1PR1, CD62L, and other chemokine receptors (15–17). Together, these data reveal a new role for *Rpl22* in regulating the progression and dissemination of T-cell malignancies.

Materials and Methods

Mouse lymphoma models and animal care

Mice were maintained in the Association for Assessment and Accreditation of Laboratory Animal Care–accredited Laboratory Animal Facility at the Fox Chase Cancer Center and were handled in compliance with guidelines established by the Institutional Animal Care and Use Committee. *MyrAkt2* Tg were generated as previously described using a proximal Lck promoter to restrict expression to T-lineage progenitors (18). Conditional ablation of the *Pten* locus in T-lineage progenitors was accomplished by crossing *Pten*^{flax/flax} mice (19) with those expressing Cre in T-lineage progenitors only, under control of the pre-T α promoter (14). Upon crossing *MyrAkt2* Tg or PTEN-deficient mice to *Rpl22*^{-/-} mice, littermates on a mixed 129-C57BL/6 background were monitored weekly for signs of disease, as described (2). Upon manifesting signs of disease, mice were sacrificed and the thymic lymphomas were excised for further analysis. All analysis of premalignant phenotypes was performed on mice at 4 to 6 weeks of age.

IHC analysis

Tissues including thymus, spleen, liver, lymph nodes, and bone marrow were collected and fixed with 10% formaldehyde. After fixation, tissues were paraffin embedded, sectioned, and stained with H&E, Ki67, anti-CD31, anti-CD3, and anti-CD45R (B220). For senescence-associated- β -galactosidase (β -Gal) staining, tissue sections were fixed for 5 minutes in 2% formaldehyde and 0.2% glutaraldehyde in PBS at room temperature, followed by overnight staining at 37°C in staining solution (40 mmol/L Na₂HPO₄, 150 mmol/L NaCl, 2 mmol/L MgCl₂, 5 mmol/L K₃Fe(CN)₆, 5 mmol/L K₄Fe(CN)₆, and 1 mg/mL X-gal (purchased from Sigma).

Flow cytometry

Single-cell suspensions were prepared from thymic lymphomas, lymph nodes, spleen and liver, and stained with optimal amounts of the following fluorochrome-conjugated antibodies: anti-CD4 (GK1.5), anti-CD8 (53-6.7), anti-Ter119 (Ter-119), anti-TCR β (H57-597), anti-CD69 (H1.2F3), anti-CD62L (MEL-14), anti-CCR7 (4B12), anti-CD3 (500A2), and anti-B220 (RA3-6B2). For

S1PR1, cells were stained with a monoclonal anti-S1PR1 antibody (FAB7089A; R&D Systems) followed by PE-conjugated rat IgG_{2A} antibody (R2a-21B2). The antibodies were purchased from eBioscience, BD Biosciences, or Biolegend. Flow cytometry was performed on stained cells using an LSRII (BD Biosciences) and analyzed using FlowJo software (Tree Star).

Plasmids, cell culture, and viral production

The S1PR1/EDG1 cDNA (RDC0053; R&D Systems) was subcloned into the bicistronic retroviral vector pMSCV-IRES-YFP (pMIY; ref. 20) using standard methods. Lentiviral shRNA constructs targeting murine S1PR1 (pLKO.1-puro) were purchased from Sigma-Aldrich. Explanted thymic lymphomas were adapted to growth *in vitro* by serial passage, and their *Rpl22* status was assessed by immunoblotting, as previously described (2) and in this article. Mouse lymphoma cells were maintained in DMEM with standard supplements including 10% FBS (Hyclone). To ectopically express S1PR1, lymphoma cells were spin infected in the presence of 8 μ g/mL polybrene with retrovirus (pMIY-S1PR1) produced by transient transfection of phoenix-ecotropic packaging cells, as described (2, 20). The infected YFP-expressing cells were electronically sorted using a FACSaria II (BD Biosciences). For knockdown experiments, lentivirus (pLKO.1-shS1PR1) was produced by transfection of HEK293T with both packaging (deltaR8.2 and VSV-G) and pLKO.1 shRNA vectors using FuGENE 6 (Roche). Virus-infected lymphoma cells were puromycin selected for at least 5 days prior to use (2).

Chemotactic migration assay

Migration assays were performed in triplicate using 24-well Transwell chambers with 5 μ m polycarbonate membranes (Corning; ref. 21). The lower chamber was filled with 600 μ L of 1% FBS DMEM supplemented with chemoattractants sphingosine 1-phosphate (S1P) or chemokine ligand 21 (CCL21; R&D Systems). Thymic lymphoma cells (1×10^5) were placed in the upper chamber and incubated for 4 hours at 37°C in 5% CO₂. Cells that migrated to the lower chamber were collected, pelleted, resuspended in FACS buffer (PBS with 1% BSA), and counted using a cytometer (LSRII; BD Biosciences) or by light microscopy.

RNA isolation and real-time PCR

Total RNA was extracted from cells using the RNeasy Mini Kit (Qiagen) according to the manufacturer's specifications. cDNA was synthesized using the Super Script II kit (Invitrogen) with Random Primers (Invitrogen), prior to RT-PCR quantification on an ABI Prism 7700 RT-PCR machine using TaqMan FAM-probes from ABI. Analysis was performed in triplicate and normalized to *Gapdh* or *Actin*. Primers and probes were from Applied Biosystems: *Gapdh*, Mm99999915_g1; *Actin*, Mm00607939_s1; *Vegfa*, Mm01281449_m1; *Hif1 α* , Mm00468869_m1; *S1p1*, Mm00514644_m1; *Klf2*, Mm01244979_g1; *Sell* (CD62L), Mm00441291_m1.

Results

Rpl22 deficiency promotes development of thymic lymphoma in *MyrAkt2* Tg mice

Monoallelic inactivation of *Rpl22* has been shown to accelerate the development of thymic lymphoma in mice expressing an oncogenic *MyrAkt2* Tg (2). Accordingly, we wished to determine how loss of the remaining *Rpl22* allele affected the development

and subsequent behavior of thymic lymphoma in mouse models. Rpl22 is required for the generation of T cells (2), as *Rpl22*-null mice exhibit a severe, p53-dependent defect in the development of $\alpha\beta$ lineage T cells in the thymus (Fig. 1A and B; ref. 5). Interestingly, enforced expression of the *MyrAkt2* Tg antagonized this p53-dependent arrest and rescued development of thymocytes from the CD4⁻CD8⁻ (double negative or DN) stage to the CD4⁺CD8⁺ (DP) stage (Fig. 1A; refs. 2, 5) and increased thymic cellularity (Supplementary Fig. S1). The *MyrAkt2* Tg also caused *Rpl22*-null mice to die faster due to the development of thymic lymphoma, which was already well developed in *MyrAkt2* Tg *Rpl22*^{+/+} and *MyrAkt2* Tg *Rpl22*^{+/-} mice, prior to the onset of any sign of disease in *MyrAkt2* Tg *Rpl22*^{+/+} mice (Fig. 1B). *MyrAkt2* Tg *Rpl22*^{-/-} mice had a median survival of 94 days versus 150 days for *MyrAkt2* Tg *Rpl22*^{+/+} mice (*, $P < 0.05$), as well as earlier disease onset (67 days vs. 113 days, respectively; Fig. 1C). Compared with *MyrAkt2* Tg *Rpl22*^{+/+} mice, *MyrAkt2* Tg *Rpl22*^{-/-} mice also exhib-


ited severe weight loss beginning at 2 months of age (Fig. 1D and E), which correlated with their poor survival (Fig. 1C).

Biallelic inactivation of *Rpl22* in *MyrAkt2* Tg mice promotes the growth of large mediastinal lymphoma masses exhibiting increased angiogenesis

Histopathologic analysis demonstrated that the large mediastinal masses that developed in *Rpl22*-deficient mice exhibited increased proliferation, as indicated by Ki67 staining (Fig. 2A) and decreased senescence indicated by senescence-associated- β -gal staining (Fig. 2B). Interestingly, while *Rpl22*^{+/+} and *Rpl22*^{+/-} tumors exhibited little evidence of angiogenesis, the large mediastinal lymphoma masses that developed in *Rpl22*^{-/-} mice exhibited substantial angiogenesis as evidenced by increased anti-CD31 staining (Fig. 2A) and by the accumulation of Ter119⁺ erythroid cells (Fig. 2C). As this has been reported for solid tumors and certain non-Hodgkin lymphomas, including T-cell

Figure 1.

Constitutively active Akt2 (*MyrAkt2*) rescues the developmental arrest of *Rpl22*-deficient thymocytes and induces thymic lymphoma. A, flow cytometry analysis of T-cell development in non-Tg and *MyrAkt2* Tg mice of the indicated genotypes. B, representative images of the thymi of non-*MyrAkt2* Tg littermates at the age of 6 weeks and *MyrAkt2* Tg mice at 12 weeks of age. C, Kaplan-Meier curves depicting percent survival of *MyrAkt2* Tg mice with the indicated genotypes ($n = 9$ for each group). The statistical significance was analyzed with the Mantel-Cox log-rank test (*MyrAkt2* Tg *Rpl22*^{-/-} versus *MyrAkt2* Tg *Rpl22*^{+/+}, **, $P < 0.005$; *MyrAkt2* Tg *Rpl22*^{+/-} versus *MyrAkt2* Tg *Rpl22*^{+/+}, **, $P < 0.005$). D, representative images of *MyrAkt2* Tg *Rpl22*^{+/+} and *MyrAkt2* Tg *Rpl22*^{-/-} mice. E, body weight of *MyrAkt2* Tg mice with the indicated genotypes: *MyrAkt2* Tg *Rpl22*^{+/+}, $n = 8$; *MyrAkt2* Tg *Rpl22*^{+/-}, $n = 12$; and *MyrAkt2* Tg *Rpl22*^{-/-}, $n = 7$. Analysis was performed using the unpaired t test (**, $P < 0.05$).






Figure 2. Thymic lymphomas in *Rpl22*-deficient mice showed enhanced proliferation and angiogenesis. A, representative images of H&E staining and IHC for Ki67 and CD31 in thymic lymphomas from *MyrAkt2 Tg* mice with the indicated *Rpl22* genotypes. B, representative images of senescence-associated β-Gal staining of thymic lymphomas from *MyrAkt2 Tg* mice with the indicated genotypes. C, flow cytometry analysis of erythroid cells (Ter119⁺) in single-cell suspensions prepared from thymic lymphomas of *MyrAkt2 Tg* mice. D, *Vegfa* mRNA levels in thymic lymphomas from *MyrAkt2 Tg* mice were quantified by real-time PCR (*MyrAkt2 Tg;Rpl22*^{+/+}, *n* = 11; *MyrAkt2 Tg;Rpl22*^{-/-}, *n* = 6). The statistical significance was assessed using an unpaired *t* test (*, *P* < 0.05). E, Western blotting revealed alterations in Hif1α expression in lymphomas from *MyrAkt2 Tg Rpl22*^{+/+} and *MyrAkt2 Tg Rpl22*^{-/-} mice. F, *Hif1* mRNA levels quantified by real-time PCR in thymic lymphomas from *MyrAkt2 Tg Rpl22*^{+/+} (*n* = 8) and *MyrAkt2 Tg Rpl22*^{-/-} (*n* = 6) mice.

lymphoma (22, 23), we asked if this was associated with increased expression of proangiogenic factors, such as VEGF. Indeed, VEGF mRNA levels were significantly enhanced in *Rpl22*^{-/-} lymphomas (Fig. 2D). The increased VEGF mRNA was associated with increased expression of the master regulator of VEGF transcription, HIF1α, whose protein but not mRNA expression was increased in *Rpl22*^{-/-} lymphomas (Fig. 2E and F), suggesting the change in expression was posttranscriptional, and resulted from hypoxia.


Rpl22 deficiency impairs tumor dissemination

Both mono- (*Rpl22*^{+/-}) and biallelic (*Rpl22*^{-/-}) inactivation of *Rpl22* accelerates lymphomagenesis in *MyrAkt2 Tg* mice; however, the lymphomas that develop exhibit distinctive behaviors. While *Rpl22*^{+/+} and *Rpl22*^{+/-} mice developed lymphomas that presented as relatively modest thymic masses with extensive dissemination to peripheral organs (2) (data not shown), *Rpl22*-deficient lymphomas accumulated mediastinally and did not disseminate to the periphery, with minimal involvement of lymph nodes, liver, and spleen (Fig. 3A and B). The hepatomegaly and splenomegaly observed in *MyrAkt2 Tg*

Rpl22^{+/+} and *MyrAkt2 Tg Rpl22*^{+/-} mice resulted from the accumulation of thymic lymphoma cells, as evidenced by increased representation of CD3⁺ cells measured by flow cytometry and IHC (data not shown). IHC analysis indicated that along with more extensive dissemination, *Rpl22*^{+/+} lymphomas also displayed increased lymphoma cell proliferation in both the spleen (Fig. 3C) and liver (data not shown).

Rpl22-deficient lymphomas also fail to disseminate in a PTEN-deficient lymphoma model

To determine if the mediastinal retention of *Rpl22*^{-/-} thymic lymphomas in the *MyrAkt2 Tg* model was also observed in other models of thymic lymphoma, we next used mice in which the *Pten* tumor suppressor gene was conditionally ablated in T-lineage progenitors using pTα-Cre (19). As with the *MyrAkt2 Tg*, ablation of the *Pten* tumor suppressor also partially rescued the defect in T-cell development caused by *Rpl22* deficiency (Fig. 4A). Moreover, as we observed in *MyrAkt2 Tg* mice, the thymic lymphomas that developed in *Rpl22*-deficient mice lacking PTEN also failed to disseminate to liver, spleen, and lymph nodes and were instead retained mediastinally (Fig. 4B–D). Finally, similar to the



lymphomas in *MyrAkt2 Tg* mice, thymic lymphomas that developed in *Pten^{-/-}Rpl22^{-/-}* mice also exhibited enhanced proliferation, as demonstrated by Ki67 staining (Fig. 4E), and angiogenesis, as evidenced by the increased presence of blood vessels marked by CD31 expression (Fig. 4F). Collectively, our data suggest that Rpl22 plays a critical role in regulating lymphoma dissemination.

Rpl22-deficient lymphomas that fail to disseminate are unresponsive to S1P ligand

Because the thymic lymphomas that develop in *Rpl22*-deficient mice are retained mediastinally and fail to disseminate, we hypothesized that this might result from a failure to respond to migratory cues. We were particularly interested in their response to S1P ligand, as it is responsible for emigration of normal mature thymocytes to the periphery (15). Indeed, Boyden chamber migration analysis revealed that while *Rpl22^{+/+}* tumor cells exhibited migration in response to S1P that was comparable with that of normal single positive (SP) T cells, *Rpl22*-deficient lymphomas failed to migrate in response to S1P ligand (Fig. 5A; refs. 24, 25). We reasoned that this might occur because Rpl22 deficiency attenuated the cellular pathways required for S1P responsiveness. Alternatively, Rpl22 deficiency might impair S1P responsiveness indirectly by facilitating transformation of Rpl22-deficient progenitors at an earlier stage than occurs for those expressing Rpl22, perhaps prior to the developmental acquisition of S1P responsiveness. To distinguish these possibilities, we assessed the phenotype of the thymic lymphomas arising in *Rpl22^{+/+}* and *Rpl22^{-/-}* mice. Interestingly, the thymic lymphomas arising in *Rpl22^{+/+}* and *Rpl22^{-/-}* mice were both phenotypically identical, with virtually all cells being CD4⁺CD8⁺ DP (Fig. 5B), suggesting that altered development was not the explanation for the failure to

respond to S1P migratory cues. This is consistent with our observation that both ectopic expression of the *MyrAkt2 Tg* and PTEN deficiency rescued the developmental arrest of Rpl22-deficient progenitors, leading to a similar distribution of thymic subsets (Fig. 1A and 4A).

To determine if Rpl22 is regulating S1P responsiveness in a more proximal manner, we investigated expression levels of S1PR1 in *Rpl22^{+/+}* and *Rpl22^{-/-}* lymphomas. Indeed, *Rpl22*-deficient thymic lymphomas exhibited reduced expression of S1PR1 mRNA (Fig. 5C). Because the expression levels of S1PR1 are highest in cells that have matured beyond the DP stage (15, 26), we asked if transformation resulted in aberrant expression of S1PR1. Indeed, we found that S1PR1 expression is elevated in DP *Rpl22^{+/+}* thymic lymphoma cells, relative to undetectable levels in their non-transformed DP counterparts (Fig. 5D). Moreover, the increased expression of S1PR1 by Rpl22-expressing DP lymphoma cells, and their capacity to migrate in response to S1P ligand *in vitro*, are correlated with the ability of these DP lymphomas to disseminate to the periphery, including into the spleen and liver (Supplementary Fig. S2A and data not shown). Conversely, DP thymic lymphomas from Rpl22-deficient mice expressed substantially reduced levels of S1PR1, failed to migrate in response to S1P ligand, and failed to emigrate to the periphery (Fig. 5A and D; Supplementary Fig. S2A). To test whether the reduced expression of S1PR1 might be responsible for the failure of Rpl22-deficient thymic lymphomas to emigrate to the periphery, we performed gain-of-function and loss-of-function analyses for S1PR1 *in vitro*. Indeed, ectopic expression of S1PR1 in Rpl22-deficient thymic lymphoma cells restored their ability to migrate in response to S1P exposure (Fig. 5E; Supplementary Fig. S2B). Moreover, knock-down of S1PR1 in Rpl22-expressing thymic lymphoma cells attenuated their ability to migrate in response to S1P (Fig. 5F). Together, these data suggest that attenuation of S1PR1 expression




Figure 4.

Rpl22 deficiency blocks thymic lymphoma dissemination to peripheral tissues in a PTEN-deficient lymphoma model. A, flow cytometry analysis of T-cell development in mice with the indicated genotypes. B, representative images of thymic lymphomas (a) and their dissemination to peripheral tissues, including lymph node (b), liver (c), and spleen (d) in *Pten*^{-/-} mice. C, representative images of thymus, lymph node, spleen, and liver from mice in B. D, quantification of organ weights as a proportion of the mouse body weight. Statistical significance was assessed by the Student *t* test (*, *P* < 0.05, *n* = 3 in each group). E, representative IHC of Ki67 staining of the thymus of *Pten*^{-/-}*Rpl22*^{+/+} and *Pten*^{-/-}*Rpl22*^{-/-} mice. F, visualization of angiogenesis in the thymus of representative PTEN-deficient mice and corresponding IHC staining for CD31.

by Rpl22 loss contributes to the migration defect observed in Rpl22-deficient lymphomas.

Rpl22 loss attenuates expression of S1PR1 by impairing expression of its transcriptional activator Klf2

To determine how Rpl22-deficiency impairs S1PR1 expression, we investigated the expression of Klf2, a transcriptional regulator of S1PR1 expression (16, 27). Klf2 mRNA and protein levels were markedly reduced in Rpl22-deficient thymic lymphomas (Fig. 6A and B). While Rpl22-sufficient DP lymphoma cells showed expression levels of Klf2 similar to normal SP cells, Rpl22 loss significantly reduced Klf2 expression in DP lymphoma cells from both *MyrAkt2* Tg mice and PTEN-deficient mice (Fig. 6B; and data not shown), as well as in more mature thymic populations undergoing positive selection (Supplementary Fig. S3A and B). S1PR1 was not the only Klf2 target reduced by Rpl22 deficiency, as another critical Klf2 target, CD62L, was also found to be down-regulated in both DP cells (data not shown) and mature thymic progenitors from *MyrAkt2* Tg mice (Supplementary Fig. S3C and


D). Klf2 expression is responsive to manipulation of Rpl22 expression in transformed cells, as ectopic expression of Rpl22 in Rpl22-deficient lymphomas restored the expression of both Klf2 and its direct target, S1PR1 (Fig. 6C). The role of Rpl22 in regulating Klf2 and S1PR1 expression is not restricted to mouse models of T-cell lymphoma. In fact, an analysis of human T-ALL cell lines harboring intact and mutant *RPL22* alleles revealed that in human T-ALL cell lines bearing *RPL22* mutations, the expression of both KLF2 and S1PR1 was reduced (Fig. 6D; Supplementary Fig. S4). Furthermore, knockdown of Rpl22 in human T-ALL cells downregulated both KLF2 and S1PR1 expression (Fig. 6E), supporting the notion that Rpl22 is regulating S1PR1 expression through effects on Klf2.

Discussion

Here we report, using two different murine models of T-ALL, that Rpl22, in addition to regulating the development of thymic lymphoma, also regulates its dissemination. This very unique

Figure 5.

Rpl22 deficiency blocks lymphoma migration through downregulation of surface S1PR1. A, analysis of migration of PTEN-deficient lymphoma cells *in vitro* in response to 24-hour exposure to S1P (20 nmol/L). Data are plotted as a percentage of input, and sorted SP thymocytes are used as positive control. B, flow cytometry analysis of thymic lymphomas that developed in PTEN-deficient mice with the indicated genotypes. C, S1PR1 mRNA levels measured by RT-PCR in mouse thymic lymphoma cells from *MyrAkt2 Tg* mice of the indicated genotypes (*MyrAkt2 Tg Rpl22*^{+/+}, *n* = 10; *MyrAkt2 Tg Rpl22*^{-/-}, *n* = 6). Significance was determined with unpaired *t* test (*, *P* < 0.05). D, immunoblots analysis of S1PR1 protein levels in DP lymphoma cells isolated from PTEN-deficient mice with indicated genotypes. SP and DP populations sorted from normal mice were used as positive and negative controls, respectively. S1PR1 expression levels were quantified by ImageJ, normalized to calnexin, and presented as fold change over the DP control. E, analysis of the migration of Rpl22-deficient lymphoma cells ectopically expressing S1PR1. Values were normalized to vehicle-treated, control-transduced *Rpl22*^{-/-} lymphomas. F, analysis of the migration of Rpl22-sufficient lymphoma cells in which S1PR1 has been knocked down. All migration assays were performed at least twice in triplicate and data are plotted after normalization to the control group (mean ± SD). Significance was determined by the Student *t* test (**, *P* < 0.05).



phenotype was observed only in *Rpl22*-deficient mice, as biallelic inactivation of *Rpl22* restricts thymic lymphoma development and progression within the primary site in the thymus, blocking dissemination in T-ALL mouse models driven by *MyrAkt2 Tg* and PTEN deficiency. The mediastinal lymphoma masses that develop in *Rpl22*^{-/-} *MyrAkt2 Tg* mice accelerate death, as is observed in *Rpl22*^{+/-} mice, but appear to do so by a very different mechanism. While *Rpl22*^{+/-} mice succumb to disseminated disease, the *Rpl22*^{-/-} mice succumb to mediastinal masses that likely induce death by suffocation, due to lung compression. Thus, we conclude that Rpl22 plays a critical role in controlling lymphoma dissemination.

We also revealed that the mediastinal retention of Rpl22-deficient lymphomas is associated with cell-autonomous alterations in the expression of key regulators of migration. Indeed, Rpl22 loss reduces the expression of the transcription factor Klf2, a master regulator that controls T-cell trafficking through its targets, the chemotactic receptor for S1PR1, which is required for thymic emigration (15), as well as other regulators of cell trafficking, including CD62L and additional chemokine receptors (16, 17,

27). Interestingly, the ability of Rpl22 to regulate Klf2 and its targets appears to be linked to transformation, as we only observed effects of Rpl22 deficiency on expression of Klf2 and its targets in our mouse transformation models. This observation may suggest that the ability of Rpl22 to regulate the Klf2-S1PR1 axis depends on contributions from the Akt signaling pathway, which is activated in both of our lymphoma models. In agreement, a previous report had implicated the PI3K/Akt pathway in regulating Klf2 expression (28). Moreover, we found that while Klf2 expression in normal DP thymocytes was quite low, its expression in Rpl22-expressing DP thymic lymphomas was significantly increased and was comparable to that in normal SP thymocytes. Importantly, KLF2 expression in thymic lymphomas was sharply attenuated by Rpl22 deficiency. The basis by which Rpl22 controls Klf2 expression remains unclear at present. Klf2 mRNA levels are reduced in *Rpl22*-deficient lymphomas, suggesting that Klf2 expression is controlled either transcriptionally or through effects on mRNA stability. Rpl22 may control Klf2 expression indirectly, by acting to facilitate the expression of a transcription factor that transactivates the *Klf2* gene. Alternatively,




Figure 6.

Rpl22 regulates S1PR1 through effects on Klf2. **A**, Klf2 mRNA levels in mouse thymic lymphomas from MyrAkt2 Tg mice (MyrAkt2 Rpl22^{+/+}, *n* = 10; MyrAkt2 Rpl22^{-/-}, *n* = 6) were quantified by RT-PCR. Statistical analysis was performed using an unpaired *t* test (*, *P* < 0.05). **B**, Western blot to assess Klf2 protein levels in lymphomas from MyrAkt2 Tg Rpl22^{+/+} and MyrAkt2 Tg Rpl22^{-/-} mice. SP and DP populations sorted from normal mice were used as positive and negative controls, respectively. **C**, S1PR1 and Klf2 mRNA levels were quantified in triplicate by RT-PCR in Rpl22-deficient lymphoma cells in which Rpl22 was reintroduced by retroviral transduction. Data are representative of three independent experiments. Significance was assessed by the Student *t* test (**, *P* < 0.005). **D**, immunoblot analysis of S1PR1 and Klf2 expression in six human T-ALL cell lines with either wild-type or mutant RPL22 alleles. **E**, analysis of S1PR1 and Klf2 protein levels by immunoblotting (left) and RNA levels (right) by RT-PCR in human T-ALL cell lines transduced with control or Rpl22 shRNA. Data are representative of two independent experiments. Significance was assessed by the Student *t* test (*, *P* < 0.05).

the control could be direct, as has been noted for other RNA-binding proteins (29), and involve Rpl22 binding to Klf2 mRNA and controlling its stability. Finally, while there is no evidence to suggest that Rpl22 is able to directly influence transcription, a recent report indicated that another RNA-binding protein, nucleolin, is not only able to bind mRNAs and regulate their translation (30), but can also bind to the Klf2 promoter in response to fluid shear stress (28). Thus, it is possible that Rpl22 is acting to regulate Klf2 expression in a similar manner. The basis by which Rpl22 regulates Klf2 expression is currently under investigation.

In both of the thymic lymphoma models we examined, Rpl22 deficiency substantially increased the mediastinal tumor burden, which was accompanied by a marked enhancement in angiogenesis. Whether the increased angiogenesis enables the expansion of the mediastinal mass or is induced by it remains unclear. The increased HIF-1/VEGF signaling we observed in the Rpl22-deficient mediastinal masses could have been induced indirectly as a result of the hypoxic conditions caused by rapid expansion of the mediastinal lymphoma mass. Consistent with this, Hif1 α mRNA levels were unchanged in Rpl22-deficient thymic lymphomas indicating a posttranscriptional mode of regulation, which usually accompanies hypoxia (31). Alternatively, we did not observe obvious necrosis in the center of the large thymic tumors from Rpl22-deficient mice, suggesting Rpl22-deficiency may directly increase angiogenesis, thereby enabling the more robust blood supply to support the development of larger tumor masses. Consistent with this possibility, we observed increased NF- κ B signaling and IL6 production in Rpl22-deficient tumors, which

could contribute to VEGF transactivation (32, 33). Efforts are in progress to distinguish these possibilities. Irrespective of the outcome of these studies, because we observe enhanced angiogenesis in Rpl22-deficient tumors, perhaps RPL22 status could be used to identify a molecularly defined subset against which to apply antiangiogenic therapy, which has not proven effective when used generally in peripheral T-cell lymphoma (34), diffuse large B-cell lymphoma (35), or mantle cell lymphoma (36).

In addition to enhancing angiogenesis, both mouse models showed that Rpl22 deficiency alters the migratory behavior of the lymphomas, causing them to be retained mediastinally, in the thymus. Mediastinal retention is one of the chief characteristics that distinguish T-lymphoblastic lymphoma (T-LBL) from T-ALL. A recent study provided some insights into the basis for this difference in localization, making the counterintuitive observation that mediastinally retained T-LBL exhibited markedly elevated expression of S1PR1, which might otherwise be expected to facilitate dissemination (37). However, these investigators reported that elevated S1PR1 expression blocked dissemination by activating ICAM1 signaling and homotypic adhesion. Accordingly, the T-LBL cases examined in this study exhibited altered migration resulting from excessive S1PR1 signaling. In contrast, mediastinal retention of Rpl22-deficient thymic lymphomas is accompanied by attenuated S1PR1 expression, and is not associated with increased ICAM1 expression (data not shown). Klf2 and its target S1PR1 are critical regulators of thymic egress that are most highly expressed in mature SP thymocytes (15, 26). Importantly, the DP thymic lymphomas that arise in MyrAkt2 Tg and

PTEN-deficient mice express far higher levels of KLF2 and S1PR1 than their nontransformed counterparts. Moreover, the migration of these DP thymic lymphomas in response to S1P ligand is comparable with that of mature SP thymocytes. In contrast, Rpl22-deficient thymic lymphomas that are retained mediastinally express markedly reduced levels of KLF2 and S1PR1 and are unable to migrate in response to S1P ligand. Importantly, their migratory capacity can be restored by ectopic expression of S1PR1, indicating that the alteration of S1PR1 is causally linked to the observed migration defect. Taken together, the cell-autonomous defects in the KLF2–S1PR1 migratory axis in Rpl22-deficient thymic lymphomas provide a plausible explanation for the failure of Rpl22-deficient thymic lymphomas to disseminate; however, it is important to note that additional factors may play a role. Indeed, KLF2 regulates the expression of other molecules that control migration, such as CD62L, which is repressed in Rpl22-deficient thymic lymphomas, and CCR7, which is induced (data not shown; refs. 38, 39). Accordingly, the failure of Rpl22-deficient lymphomas to disseminate *in vivo* may involve alterations in responsiveness to these or other chemokines. Finally, it is also possible that cell-extrinsic factors might be involved. For example, Rpl22-deficient thymic stroma may express an altered complement of chemokines, cytokines, or adhesion molecules that might fail to promote migration or, alternatively, actively retain the Rpl22-deficient lymphomas. Efforts are currently ongoing to identify other molecular effectors of migration whose expression is altered in Rpl22-deficient lymphomas or in Rpl22-deficient thymic stroma.

Collectively, we have found that Rpl22 haploinsufficiency and deficiency both facilitate development of T-lymphoid tumors that kill their hosts, but by fundamentally distinct mechanisms, with haploinsufficiency killing through dissemination and Rpl22-deficiency killing through mediastinal retention. The mediastinal mass is one of the key characteristics of T-LBL, along with no or minimal marrow involvement. While we have previously identified RPL22 haploinsufficiency in about 10% of T-ALL, the extent of RPL22 inactivation in T-LBL has not been assessed. Nevertheless, our data also suggest that Rpl22 may play an important role in the dissemination of human leukemias/lymphomas. This is of particular interest in T-cell leukemia, where chemokines and chemokine receptors like CCR9/CCL19 and CXCR4/CXCL12 influence T-cell leukemia maintenance and progression (39–41). Given that S1PR1 sig-

naling has also been linked to the dissemination of solid tumors (42, 43), Rpl22 loss may affect the metastasis of solid tumors as well. Indeed, biallelic inactivation of *RPL22* has been reported in colorectal cancer (8, 9); however, its association with metastatic spread and disease course has not been evaluated. Future efforts will be directed toward evaluating the link between *RPL22* inactivation and dissemination in both hematologic and solid malignancies.

Disclosure of Potential Conflicts of Interest

No potential conflicts of interest were disclosed.

Authors' Contributions

Conception and design: S. Rao, J.E. Stadanlick, D.L. Wiest

Development of methodology: S. Rao, K.Q. Cai, S.-Y. Lee

Acquisition of data (provided animals, acquired and managed patients, provided facilities, etc.): S. Rao, K.Q. Cai, J.E. Stadanlick, N. Solanki-Patel, J.R. Testa

Analysis and interpretation of data (e.g., statistical analysis, biostatistics, computational analysis): S. Rao, K.Q. Cai, S.P. Fahl, D.L. Wiest

Writing, review, and/or revision of the manuscript: S. Rao, J.R. Testa, D.L. Wiest

Administrative, technical, or material support (i.e., reporting or organizing data, constructing databases): S. Rao, N. Greenberg-Kushnir

Study supervision: D.L. Wiest

Acknowledgments

The authors thank Dr. Siddharth Balachandran for critical review of the manuscript, Dr. Hans-Jorg Fehling for providing pTα-Cre mice, and Dr. Antonio Di Cristofano for *Pten^{flax/flax}* mice. They gratefully acknowledge the assistance of the following core facilities of the Fox Chase Cancer Center: Cell Culture, DNA Sequencing, Flow Cytometry, and Laboratory Animal.

Grant Support

This work was supported by NIH grants R01AI110985 and core grant P30CA006927, Leukemia and Lymphoma Society grant 6057-14, and an appropriation from the Commonwealth of Pennsylvania. J.R. Testa and D.L. Wiest also received support from NIH grant R01CA077429 for the development and characterization of the MyrAkt2 Tg mouse model. S. Rao was supported by a Department of Defense Bone Marrow Failure Postdoctoral Fellowship W81XWH-13-1-0403.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked *advertisement* in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Received September 30, 2015; revised March 22, 2016; accepted March 25, 2016; published OnlineFirst April 5, 2016.

References

1. Kenmochi N. [Ribosomopathies—defective ribosome biogenesis and diseases]. *Seikagaku* 2013;85:909–15.
2. Rao S, Lee SY, Gutierrez A, Perrigoue J, Thapa RJ, Tu Z, et al. Inactivation of ribosomal protein L22 promotes transformation by induction of the stemness factor, Lin28B. *Blood* 2012;120:3764–73.
3. Kondrashov N, Pusic A, Stumpf CR, Shimizu K, Hsieh AC, Xue S, et al. Ribosome-mediated specificity in Hox mRNA translation and vertebrate tissue patterning. *Cell* 2011;145:383–97.
4. Zhang Y, Duc AC, Rao S, Sun XL, Bilbee AN, Rhodes M, et al. Control of hematopoietic stem cell emergence by antagonistic functions of ribosomal protein paralogs. *Dev Cell* 2013;24:411–25.
5. Anderson SJ, Lauritsen JP, Hartman MG, Foushee AM, Lefebvre JM, Shinton SA, et al. Ablation of ribosomal protein L22 selectively impairs alphabeta T cell development by activation of a p53-dependent checkpoint. *Immunity* 2007;26:759–72.
6. Fahl SP, Harris B, Coffey F, Wiest DL. Rpl22 Loss impairs the development of B lymphocytes by activating a p53-dependent checkpoint. *J Immunol* 2015;194:200–9.
7. Amsterdam A, Sadler KC, Lai K, Farrington S, Bronson RT, Lees JA, et al. Many ribosomal protein genes are cancer genes in zebrafish. *PLoS Biol* 2004;2:E139.
8. Ferreira AM, Tuominen I, van Dijk-Bos K, Sanjabi B, van der Sluis T, van der Zee AG, et al. High frequency of RPL22 mutations in microsatellite-unstable colorectal and endometrial tumors. *Hum Mutat* 2014;35:1442–5.
9. Novetsky AP, Zigelboim I, Thompson DMJr., Powell MA, Mutch DG, Goodfellow PJ. Frequent mutations in the RPL22 gene and its clinical and functional implications. *Gynecol Oncol* 2013;128:470–4.
10. Rahman N, Scott RH. Cancer genes associated with phenotypes in mono-allelic and biallelic mutation carriers: new lessons from old players. *Human Mol Genet* 2007;16:R60–6.
11. Gianetti E, Hall JE, Au MG, Kaiser UB, Quinton R, Stewart JA, et al. When genetic load does not correlate with phenotypic spectrum: lessons from the GnRH receptor (GNRHR). *J Clin Endocrinol Metab* 2012;97:E1798–807.

12. Gutierrez A, Sanda T, Grebliunaite R, Carracedo A, Salmena L, Ahn Y, et al. High frequency of PTEN, PI3K, and AKT abnormalities in T-cell acute lymphoblastic leukemia. *Blood* 2009;114:647–50.
13. Timakhov RA, Tan Y, Rao M, Liu Z, Altomare DA, Pei J, et al. Recurrent chromosomal rearrangements implicate oncogenes contributing to T-cell lymphomagenesis in Lck-MyrAkt2 transgenic mice. *Genes Chromosomes Cancer* 2009;48:786–94.
14. Luche H, Nageswara Rao T, Kumar S, Tasdogan A, Beckel F, Blum C, et al. In vivo fate mapping identifies pre-TCRalpha expression as an intra- and extrathymic, but not prethymic, marker of T lymphopoiesis. *J Exp Med* 2013;210:699–714.
15. Matloubian M, Lo CG, Cinamon G, Lesneski MJ, Xu Y, Brinkmann V, et al. Lymphocyte egress from thymus and peripheral lymphoid organs is dependent on S1P receptor 1. *Nature* 2004;427:355–60.
16. Bai A, Hu H, Yeung M, Chen J. Kruppel-like factor 2 controls T cell trafficking by activating L-selectin (CD62L) and sphingosine-1-phosphate receptor 1 transcription. *J Immunol* 2007;178:7632–9.
17. Sebzda E, Zou Z, Lee JS, Wang T, Kahn ML. Transcription factor KLF2 regulates the migration of naive T cells by restricting chemokine receptor expression patterns. *Nat Immunol* 2008;9:292–300.
18. Tan Y, Timakhov RA, Rao M, Altomare DA, Xu J, Liu Z, et al. A novel recurrent chromosomal inversion implicates the homeobox gene *Dlx5* in T-cell lymphomas from Lck-Akt2 transgenic mice. *Cancer Res* 2008;68:1296–302.
19. Tiozzo C, Danopoulos S, Lavarreda-Pearce M, Baptista S, Varimezova R, Al Alam D, et al. Embryonic epithelial Pten deletion through *Nkx2.1*-cre leads to thyroid tumorigenesis in a strain-dependent manner. *Endocr Relat Cancer* 2012;19:111–22.
20. Stadanlick JE, Zhang Z, Lee SY, Hemann M, Biery M, Carleton MO, et al. Developmental arrest of T cells in *Rpl22*-deficient mice is dependent upon multiple p53 effectors. *J Immunol* 2011;187:664–75.
21. Visentin B, Vekich JA, Sibbald BJ, Cavalli AL, Moreno KM, Matteo RG, et al. Validation of an anti-sphingosine-1-phosphate antibody as a potential therapeutic in reducing growth, invasion, and angiogenesis in multiple tumor lineages. *Cancer Cell* 2006;9:225–38.
22. Ribatti D, Nico B, Ranieri G, Specchia G, Vacca A. The role of angiogenesis in human non-Hodgkin lymphomas. *Neoplasia* 2013;15:231–8.
23. Aggarwal D, Srivastava G, Gupta R, Pant L, Krishan G, Singh S. Angiogenesis in non-Hodgkin's lymphoma: an intercategory comparison of microvessel density. *ISRN Hematol* 2012;2012:943089.
24. Pham TH, Okada T, Matloubian M, Lo CG, Cyster JG. S1P1 receptor signaling overrides retention mediated by G alpha i-coupled receptors to promote T cell egress. *Immunity* 2008;28:122–33.
25. Graeler M, Shankar G, Goetzl EJ. Cutting edge: suppression of T cell chemotaxis by sphingosine 1-phosphate. *J Immunol* 2002;169:4084–7.
26. Kurobe H, Liu C, Ueno T, Saito F, Ohgashi I, Seach N, et al. CCR7-dependent cortex-to-medulla migration of positively selected thymocytes is essential for establishing central tolerance. *Immunity* 2006;24:165–77.
27. Carlson CM, Endrizzi BT, Wu J, Ding X, Weinreich MA, Walsh ER, et al. Kruppel-like factor 2 regulates thymocyte and T-cell migration. *Nature* 2006;442:299–302.
28. Huddleson JP, Ahmad N, Lingrel JB. Up-regulation of the KLF2 transcription factor by fluid shear stress requires nucleolin. *J Biol Chem* 2006;281:15121–8.
29. Leppik K, Schott J, Reitter S, Poetz F, Hammond MC, Stoecklin G. Roquin promotes constitutive mRNA decay via a conserved class of stem-loop recognition motifs. *Cell* 2013;153:869–81.
30. Chen J, Guo K, Kastan MB. Interactions of nucleolin and ribosomal protein L26 (RPL26) in translational control of human p53 mRNA. *J Biol Chem* 2012;287:16467–76.
31. Lin C, McGough R, Aswad B, Block JA, Terek R. Hypoxia induces HIF-1alpha and VEGF expression in chondrosarcoma cells and chondrocytes. *J Orthop Res* 2004;22:1175–81.
32. Loeffler S, Fayard B, Weis J, Weissenberger J. Interleukin-6 induces transcriptional activation of vascular endothelial growth factor (VEGF) in astrocytes in vivo and regulates VEGF promoter activity in glioblastoma cells via direct interaction between STAT3 and Sp1. *Int J Cancer* 2005;115:202–13.
33. Wei LH, Kuo ML, Chen CA, Chou CH, Lai KB, Lee CN, et al. Interleukin-6 promotes cervical tumor growth by VEGF-dependent angiogenesis via a STAT3 pathway. *Oncogene* 2003;22:1517–27.
34. Hopfinger G, Nosslinger T, Lang A, Linkesch W, Melchardt T, Weiss L, et al. Lenalidomide in combination with vorinostat and dexamethasone for the treatment of relapsed/refractory peripheral T cell lymphoma (PTCL): report of a phase I/II trial. *Ann Hematol* 2014;93:459–62.
35. Ganjoo KN, An CS, Robertson MJ, Gordon LI, Sen JA, Weisenbach J, et al. Rituximab, bevacizumab and CHOP (RA-CHOP) in untreated diffuse large B-cell lymphoma: safety, biomarker and pharmacokinetic analysis. *Leuk Lymphoma* 2006;47:998–1005.
36. Ruan J, Gregory SA, Christos P, Martin P, Furman RR, Coleman M, et al. Long-term follow-up of R-CHOP with bevacizumab as initial therapy for mantle cell lymphoma: clinical and correlative results. *Clin Lymphoma Myeloma Leuk* 2014;14:107–13.
37. Feng H, Stachura DL, White RM, Gutierrez A, Zhang L, Sanda T, et al. T-lymphoblastic lymphoma cells express high levels of BCL2, S1P1, and ICAM1, leading to a blockade of tumor cell intravasation. *Cancer Cell* 2010;18:353–66.
38. Calderon L, Boehm T. Three chemokine receptors cooperatively regulate homing of hematopoietic progenitors to the embryonic mouse thymus. *Proc Natl Acad Sci U S A* 2011;108:7517–22.
39. Passaro D, Irigoyen M, Catherinet C, Gachet S, Da Costa De Jesus C, Lasgi C, et al. CXCR4 is required for leukemia-initiating cell activity in t cell acute lymphoblastic leukemia. *Cancer Cell* 2015;27:769–79.
40. Pitt LA, Tikhonova AN, Hu H, Trimarchi T, King B, Gong Y, et al. CXCL12-producing vascular endothelial niches control acute T cell leukemia maintenance. *Cancer cell* 2015;27:755–68.
41. Buonamici S, Trimarchi T, Ruocco MG, Reavie L, Cathelin S, Mar BG, et al. CCR7 signalling as an essential regulator of CNS infiltration in T-cell leukaemia. *Nature* 2009;459:1000–4.
42. Gao D, Nolan DJ, Mellick AS, Bambino K, McDonnell K, Mittal V. Endothelial progenitor cells control the angiogenic switch in mouse lung metastasis. *Science* 2008;319:195–8.
43. Deng J, Liu Y, Lee H, Herrmann A, Zhang W, Zhang C, et al. S1PR1-STAT3 signaling is crucial for myeloid cell colonization at future metastatic sites. *Cancer cell* 2012;21:642–54.